

**Supplementary table S1.** Comparison between haematopoietic stem cell transplantation (HSCT), monthly intravenous pulses and daily oral administration regimens of cyclophosphamide.

|                           | Pulse                          |             | IV monthly            | PO regimen    |
|---------------------------|--------------------------------|-------------|-----------------------|---------------|
|                           | ASTIS trial                    | SCOT trial  |                       |               |
| Single dose               | 4 g/m <sup>2</sup> + 200 mg/kg | 120 mg/kg   | 750 mg/m <sup>2</sup> | 2 mg/kg/day   |
| Duration                  | 5 days                         | <5 days     | 12 months             | 12 months     |
| Potential cumulative dose | 17.3 – 21.4 g                  | 6.6 – 8.4 g | 14.2 – 16.6 g         | 40.1 – 51.1 g |

Assuming an average woman (162cm x 55 kg) and an average man (175 cm x 70 kg).

IV: intravenous; PO: oral.

**Appendix 1.** Independent variables modelled in the regression analysis.

- Gender (male, female)
- Disease duration (years)
- Age at baseline (years)
- Route of cyclophosphamide administration (oral or intravenous)
- Mean monthly dosage of cyclophosphamide (for both oral and intravenous)
- Mean daily dosage of cyclophosphamide (for both oral and intravenous)
- Cumulative dosage of cyclophosphamide
- Duration of treatment with cyclophosphamide
- Forced vital capacity (at baseline and at end of treatment)
- Lung diffusion of carbon oxyde (DLCO) (at baseline and at end of treatment)
- Steroid use (at baseline, at end of treatment, at follow-up visit)
- Steroid dosage (at baseline, at end of treatment, at follow-up visit)
- DMARDs use (prior to baseline, at baseline, at end of treatment, at follow-up visit)
- Race (African-American, Caucasian, other)
- Skin involvement subset (limited, diffuse)
- Modified Rodnan skin score (at baseline, at end of treatment)
- Anti-Scl70 antibody positivity
- Anti-centromere positivity
- Anti- RNA polymerase III positivity
- Gastric-oesophageal involvement (history or presence at baseline)
- Intestinal involvement (history or presence at baseline)
- Muscular involvement (history or presence at baseline)
- Interstitial lung involvement (history or presence at baseline)
- Joint involvement (history or presence at baseline)
- Cardiac involvement (history or presence at baseline)
- Digital ulcers (history or presence at baseline)
- Pulmonary arterial hypertension (history or presence at baseline)
- Smoking status (history or presence at baseline)

## List of collaborators (in alphabetical order)

Paolo Airò, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia, Brescia, Italy;

Alexandra Balbir-Gurmann, B. Shine Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of Medicine-Technion, Haifa, Israel;

Patricia E. Carreira, Servicio de Reumatología, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Spain;

Laura Cometi, Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Italy;

M. Kari Connolly, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA;

Franco Cozzi, Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy;

Aryeh Fischer, Bristol-Myers Squibb Company, Princeton, NJ, USA;

Tracy Frech, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA;

Ana M. Gheorghiu, Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;

Jeffrey Golden, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA;

Francesca Ingegnoli, Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Dept of Clinical Sciences & Community Health, Università degli Studi di Milano, Italy;

Ruxandra Ionescu, Spital Clinic Sf. Maria, Bd Ion Mihalache 37-39, Etaj 1, 011172, Bucuresti, Romania;

Suzanne Kafaja, Department of Medicine, David Geffen School of Medicine at UCLA, Division of Rheumatology, University of California, Los Angeles (CA), USA;

Dinesh Khanna, Department of Medicine, University of Michigan Medical School, Ann Arbor, MI USA;

Maria Grazia Lazzaroni, Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia, and University of Brescia, Italy;

Esthela Loyo, Servicio de Reumatología e Inmunología Clínica, Hospital Regional Universitario José María Cabral y Báez, Santiago de los Caballeros, Santiago, República Dominicana;

Maureen Mayes, Department of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA;

Carina Mihai, Department of Rheumatology, Zurich University Hospital, Switzerland; Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania;

Jerry Molitor, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA;

Francisca M. Moraes-Fontes, Unidade de Doenças Auto-imunes/ Medicina 7.2. Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisboa, Portugal;

M.A. Olman, Department of Medicine, University of Alabama, Birmingham, AL, USA;

Glenny Paulino, Servicio de Reumatología e Inmunología Clínica, Hospital Regional Universitario José María Cabral y Báez, Santiago de los Caballeros, Santiago, República Dominicana;

Pamela Polito, Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy; pamela.polito@libero.it

Hadi Poormoghim, Rheumatology Unit, Firozgar Hospital, Tehran Iran;

Simona Rednic, Universitatea de Medicina si Farmacie Iuliu Hatieganu Facultatea de Medicina, Cluj-Napoca, Romania;

Gabriela Riemekasten, Department of Rheumatology and Clinical Immunology, University of Lübeck, Germany;

Dean E. Schraufnagel, Department of Medicine, University of Illinois College of Medicine at Chicago, IL, USA;

James R. Seibold, Scleroderma Research Consultants, Aiken, SC, USA;

Richard M. Silver, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA;

Kamal Solanki, Rheumatology Department, Waikato Hospital, Hamilton, New Zealand;

Arthur C. Theodore, Department of Medicine, Boston University School of Medicine, Boston, MA, USA;

Chi Hong Tseng, Department of Medicine, David Geffen School of Medicine at UCLA, Division of Pulmonary & Critical Care Medicine, University of California, Los Angeles CA, USA;

John Varga, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;

Elizabeth Volkmann, Department of Medicine, David Geffen School of Medicine at UCLA, Division of Pulmonary & Critical Care Medicine, University of California, Los Angeles, USA;

Suncica Volkov, Department of Medicine, University of Illinois College of Medicine at Chicago, IL, USA;

Robert A. Wise, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Sule Yavuz, Department of Rheumatology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey;

Elisabetta Zanatta, Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy.